MannKind (MNKD) Resumen de Acciones
MannKind Corporation, empresa biofarmacéutica, se centra en el suministro de diversas soluciones para transformar la atención a las enfermedades crónicas. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 0/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
MNKD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5362.5% infravalorado descuento intrínseco
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCompetidores de MannKind Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$2.86 |
| Máximo en las últimas 52 semanas | US$6.51 |
| Mínimo de 52 semanas | US$2.23 |
| Beta | 1.04 |
| Cambio en 1 mes | 14.40% |
| Variación en 3 meses | -50.52% |
| Cambio de 1 año | -40.17% |
| Variación en 3 años | -24.74% |
| Variación en 5 años | -35.00% |
| Variación desde la OPV | -95.94% |
Noticias y actualizaciones recientes
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.Recent updates
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
Feb 06MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
Sep 03
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
May 11MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
Mar 01MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Dec 17MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Rentabilidad de los accionistas
| MNKD | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 2.5% | 0.8% | 1.8% |
| 1Y | -40.2% | 39.2% | 29.8% |
Rentabilidad vs. Industria: Los resultados de MNKD fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 39.2% el año pasado.
Rentabilidad vs. Mercado: MNKD obtuvo unos resultados inferiores a los del mercado US, que fueron del 29.8% el año pasado.
Volatilidad de los precios
| MNKD volatility | |
|---|---|
| MNKD Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de MNKD ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MNKD(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1991 | 592 | Michael Castagna | mannkindcorp.com |
MannKind Corporation, empresa biofarmacéutica, se centra en el suministro de diversas soluciones para transformar la atención de las enfermedades crónicas. Desarrolla y comercializa tratamientos que abordan graves necesidades médicas no cubiertas, como la diabetes, la hipertensión pulmonar y la sobrecarga de líquidos en la insuficiencia cardiaca y la enfermedad renal crónica. Ofrece el polvo para inhalación Afrezza, una insulina inhalada utilizada para mejorar el control glucémico en adultos con diabetes; y el dispositivo portátil de administración de insulina V-Go, que proporciona infusión subcutánea continua de insulina en adultos.
Resumen de fundamentos de MannKind Corporation
| Estadísticas fundamentales de MNKD | |
|---|---|
| Capitalización bursátil | US$883.16m |
| Beneficios(TTM) | US$5.86m |
| Ingresos (TTM) | US$348.97m |
150.6x
Ratio precio-beneficio (PE)2.5x
Ratio precio-ventas (PS)¿Está MNKD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MNKD | |
|---|---|
| Ingresos | US$348.97m |
| Coste de los ingresos | US$87.96m |
| Beneficio bruto | US$261.01m |
| Otros gastos | US$255.14m |
| Beneficios | US$5.86m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
May 06, 2026
| Beneficios por acción (BPA) | 0.019 |
| Margen bruto | 74.79% |
| Margen de beneficio neto | 1.68% |
| Ratio deuda/patrimonio | -695.1% |
¿Cómo se ha desempeñado MNKD a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/05 21:15 |
| Precio de las acciones al final del día | 2026/05/05 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
MannKind Corporation está cubierta por 29 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |